ADVERTISEMENT
China’s Churning Out Revolutionary Cancer Drugs Much Cheaper Than the U.S.
Developing a world-class pharma business is a priority for China and one way firms plan to elbow into the market is lower pricing.
06 Jun 2019, 10:28 PM IST
(Bloomberg Businessweek) -- Western companies last year began selling some of their hottest cancer drugs, called PD-1 inhibitors, with much fanfare in China. But rather than quickly conquering the mainland market, American drugmakers Merck & Co. and Bristol-Myers Squibb Co. have found themselves facing a surprising challenge: local competitors. Chinese companies are introducing patented cancer therapies in their home market based on ...
I’m already a Subscriber Sign In
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Ad-Lite
Experience
Members-Only
Rewards
NDTV Profit
Exclusive Stories
Full Access to
NDTV Profit App
Access to
Stories
20,000+
Research Reports
Ad-Lite
Experience
NDTV Profit
Exclusive Stories
Curated
Newsletters
Priority Pass
to Special Events
Members-Only
Rewards
Full Access to
NDTV Profit App
Still Not convinced ? Know More
Get live Stock market updates, Business news, Today’s latest news, Trending stories, and Videos on NDTV Profit.
ADVERTISEMENT